bioAffinity Technologies Executes Agreement with Fosun Long March to Evaluate CyPath® Lung for Commercialization in China
China’s leading healthcare company to evaluate bioAffinity’s non-invasive, highly accurate test for early-stage lung cancer with aim to commercialize in...







